JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB288148

Human IgG4, kappa - Isotype Control antibody [MOPC-21]

Be the first to review this product! Submit a review

|

(1 Publication)

Human IgG4, kappa - Isotype Control antibody [MOPC-21] Cited in 1 publication.

View Alternative Names

Immunoglobulin heavy constant gamma 4, Ig gamma-4 chain C region, IGHG4

Key facts

Host species

Human

Clonality

Monoclonal

Clone number

MOPC-21

Isotype

IgG4

Light chain type

kappa

Carrier free

No

Applications

Flow Cyt, WB

applications

Product details

Key features and details:

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply.
  • Human monoclonal [MOPC-21] to IgG4 kappa.
  • Suitable for: WB, Flow Cyt.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
Preservative: 0.02% Proclin 300 Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Storage information
Avoid freeze / thaw cycle

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound Igs serve as receptors, which upon binding to a specific antigen trigger the clonal expansion and differentiation of B lymphocytes into Ig-secreting plasma cells. Secreted Igs known as antibodies mediate the effector phase of humoral immunity by blocking the interaction of infectious antigens with cellular receptors (via the antigen-binding region) and eliciting effector mechanisms that lead to pathogen neutralization (via the constant region) (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The antigen-binding region is formed by the variable domain of one heavy chain paired with the variable domain of its associated light chain. Each Ig molecule has two antigen-binding sites with remarkable affinity for a particular antigen due to V-(D)-J rearrangement, somatic hypermutations and affinity maturation of the variable domains upon antigen exposure (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region defines the Ig isotype that perform distinct sets of effector functions. B cells diversify and rearrange their Ig constant regions through class-switch recombination, a process by which the constant region is switched from one Ig isotype to another, namely from IgM and IgD to IgG, IgA and IgE (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region interacts (via the fragment crystallizable, Fc) with the Fc receptors on innate immune cells to mediate humoral effector functions. Ig gamma-4 (IgG4) isotype does not elicit antibody-dependent cellular cytotoxicity (ADDC) or complement-dependent cytotoxicity (CDC). Instead it is likely involved in immune tolerance mechanisms to allergens and parasites either by blocking IgE-antigen complex formation or by directly inhibiting mast cell degranulation through Fc receptor signaling. In the context of tumorigenesis, it may participate in immunosuppressive mechanisms.
See full target information IGHG4

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Basic research in cardiology 120:263-286 PubMed38520533

2024

Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin.

Applications

Unspecified application

Species

Unspecified reactive species

Panagiotis Efentakis,Angeliki Choustoulaki,Grzegorz Kwiatkowski,Aimilia Varela,Ioannis V Kostopoulos,George Tsekenis,Ioannis Ntanasis-Stathopoulos,Anastasios Georgoulis,Constantinos E Vorgias,Harikleia Gakiopoulou,Alexandros Briasoulis,Constantinos H Davos,Nikolaos Kostomitsopoulos,Ourania Tsitsilonis,Meletios Athanasios Dimopoulos,Evangelos Terpos,Stefan Chłopicki,Maria Gavriatopoulou,Ioanna Andreadou
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com